The Clinical Practice Research Datalink (CPRD)


CPRD, managed by the Department of Health, United Kingdom (UK), contains over 5 million active patient records (and over 13 million overall) drawn from approximately 650 primary care practices in the UK. The Medicines and Healthcare Products Regulatory Agency manages the CPRD and has initiated a program to enable broader research use of the data both within the UK and overseas. The CPRD is the world's largest database of anonymized, longitudinal primary care medical records, also linking to secondary care datasets. The database has clinical and prescription data and can provide information to support pharmacovigilance (indication, utilization, and risk/benefit profiles of drugs) and formal pharmacoepidemiologic studies, including information on demographics, medical symptoms, therapy (medicines, vaccines, devices), and treatment outcomes. It can further support services to enhance clinical trials efficiency (protocol optimization, feasibility and recruitment). The CPRD can provide data for both clinical and academic researchers and over 1,100 articles published in peer-reviewed journals have used data from the CPRD. For academic researchers, simple feasibility counts of patients and events for specified diseases or prescriptions are free of charge. Aggregated data tables can be provided, at a cost that varies with the complexity of the request. Patient-level data sets also can be provided.

Selected References


Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed anginaExternal Web Site Policy. Cancer. 2005 Mar 15;103(6):1114-21.


Kaye JA, Jick H. Antibiotics and the risk of breast cancerExternal Web Site Policy. Epidemiology. 2005 Sep;16(5):688-90.

Gonzalez-Perez A, Garcia Rodriguez LA. Breast cancer risk among users of antidepressant medicationsExternal Web Site Policy. Epidemiology. 2005 Jan;16(1):101-5.

van Staa TP, Card T, Logan RF, Leufkens HG. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological studyExternal Web Site Policy. Gut. 2005 Nov;54(11):1573-8.

Meier CR, Derby LE, Jick SS, Jick H. Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancerExternal Web Site Policy. Arch Intern Med. 2000 Feb 14;160(3):349-53.

Langman MJ, Cheng KK, Gilman EA, Lancashire RJ. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research databaseExternal Web Site Policy. BMJ. 2000 Jun 17;320(7250):1642-6.

Garcia-Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugsExternal Web Site Policy. Epidemiology. 2001 Jan;12(1):88-93.

Meier CR, Schmitz S, Jick H. Association between acetaminophen or nonsteroidal antiinflammatory drugs and risk of developing ovarian, breast, or colon cancerExternal Web Site Policy. Pharmacotherapy. 2002 Mar;22(3):303-9.

Kaye JA, Myers MW, Jick H. Acetaminophen and the risk of renal and bladder cancer in the general practice research databaseExternal Web Site Policy. Epidemiology. 2001 Nov;12(6):690-4.

Kaye JA, Jick H. Statin use and cancer risk in the General Practice Research DatabaseExternal Web Site Policy. Br J Cancer. 2004 Feb 9;90(3):635-7.

Gelfand JM, Shin DB, Neimann AL, Wang X, Margolis DJ, Troxel AB. The risk of lymphoma in patients with psoriasisExternal Web Site Policy. J Invest Dermatol. 2006 Oct;126(10):2194-201.

Hogler W, Wehl G, van Staa T, Meister B, Klein-Franke A, Kropshofer G. Incidence of skeletal complications during treatment of childhood acute lymphoblastic leukemia: comparison of fracture risk with the General Practice Research DatabaseExternal Web Site Policy. Pediatr Blood Cancer. 2007 Jan;48(1):21-7.

Gonzalez-Perez A, Garcia Rodriguez LA. Prostate cancer risk among men with diabetes mellitus (Spain)External Web Site Policy. Cancer Causes Control. 2005 Nov;16(9):1055-8.

Population Burden

Lewis JD, Bilker WB, Weinstein RB, Strom BL. The relationship between time since registration and measured incidence rates in the General Practice Research DatabaseExternal Web Site Policy. Pharmacoepidemiol Drug Saf. 2005 Jul;14(7):443-51.

West J, Logan RF, Smith CJ, Hubbard RB, Card TR. Malignancy and mortality in people with coeliac disease: population based cohort studyExternal Web Site Policy. BMJ. 2004 Sep 25;329(7468):716-9. Epub 2004 Jul 21.

Kaye JA, Derby LE, del Mar Melero-Montes M, Quinn M, Jick H. The incidence of breast cancer in the General Practice Research Database compared with national cancer registration dataExternal Web Site Policy. Br J Cancer. 2000 Dec;83(11):1556-8.

Cost/Cost Effectiveness

Tooley PJ, Cookson RF, Jones M, Nuyts GD. Medical events and resource utilisation in cancer-pain patients treated with strong opioids: an analysis of the UK General Practice Research Database. J Outcomes Res. 2000;4:1-14.

Dolan P, Torgerson DJ, Wolstenholme J. Costs of breast cancer treatment in the United KingdomExternal Web Site Policy. Breast. 1999 Aug;8(4):205-7.

Return to Top